Direkt zum Inhalt
Merck

Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy.

Science translational medicine (2014-10-17)
S Armando Villalta, Wendy Rosenthal, Leonel Martinez, Amanjot Kaur, Tim Sparwasser, James G Tidball, Marta Margeta, Melissa J Spencer, Jeffrey A Bluestone
ZUSAMMENFASSUNG

We examined the hypothesis that regulatory T cells (Tregs) modulate muscle injury and inflammation in the mdx mouse model of Duchenne muscular dystrophy (DMD). Although Tregs were largely absent in the muscle of wild-type mice and normal human muscle, they were present in necrotic lesions, displayed an activated phenotype, and showed increased expression of interleukin-10 (IL-10) in dystrophic muscle from mdx mice. Depletion of Tregs exacerbated muscle injury and the severity of muscle inflammation, which was characterized by an enhanced interferon-γ (IFN-γ) response and activation of M1 macrophages. To test the therapeutic value of targeting Tregs in muscular dystrophy, we treated mdx mice with IL-2/anti-IL-2 complexes and found that Tregs and IL-10 concentrations were increased in muscle, resulting in reduced expression of cyclooxygenase-2 and decreased myofiber injury. These findings suggest that Tregs modulate the progression of muscular dystrophy by suppressing type 1 inflammation in muscle associated with muscle fiber injury, and highlight the potential of Treg-modulating agents as therapeutics for DMD.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Creatin, anhydrous
Sigma-Aldrich
3-Amino-9-ethylcarbazol, ≥95% (HPLC), powder
Sigma-Aldrich
3-Amino-9-ethylcarbazol, tablet
Sigma-Aldrich
Interleukin-2 aus mouse, IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-2 aus mouse, IL-2, recombinant, expressed in E. coli, carrier free